🔗 Share this article World Health Organization Sounds Warning Over Severe Lack of Weight-Loss Jabs Under one in 10 patients that would benefit from weight-loss injections including Wegovy are able to get them, states the WHO as it issues its first advice on the therapies. Considering over a billion individuals worldwide now obese, it is calling for more widespread and fairer availability to GLP-1 medication. Based on forecasts, in excess of 2,000,000,000 will be obese by 2030 unless action is taken. "Our latest guidelines affirms that obesity is a chronic disease that can be treated with holistic and lifelong care," remarked WHO director-general Tedros Adhanom Ghebreyesus. Significant expense, constrained manufacturing, and supply-chain constraints are major barriers to widespread access to the jabs that can aid individuals in losing considerable body mass, notes the body. GLP-1 Therapy Shortage Even in the current best projected scenario, the production of GLP-1 therapies might only reach about 100 million people – under 10% of those who need them, according to the health organization. The guideline calls on countries and companies to increase access, via approaches such as voluntary licensing. A patent on semaglutide – the core component of the drug Wegovy – is scheduled to end in a number of countries in 2026. The Way Obesity Drugs Operate GLP-1 drugs mimick a biological compound to slow digestion, reduce hunger and increase feelings of fullness so individuals reduce food intake. People commonly begin shedding pounds within a few weeks of starting on the regular doses. Research suggests patients may see weight return within a year of stopping the medication, when their usual hunger come back. To be above a healthy weight increases your chance for experiencing medical conditions, like type 2 diabetes, cardiovascular issues, brain attack, and some malignancies. Obesity impacts individuals in all nations and was linked to millions of fatalities worldwide in 2024, per the WHO.
Under one in 10 patients that would benefit from weight-loss injections including Wegovy are able to get them, states the WHO as it issues its first advice on the therapies. Considering over a billion individuals worldwide now obese, it is calling for more widespread and fairer availability to GLP-1 medication. Based on forecasts, in excess of 2,000,000,000 will be obese by 2030 unless action is taken. "Our latest guidelines affirms that obesity is a chronic disease that can be treated with holistic and lifelong care," remarked WHO director-general Tedros Adhanom Ghebreyesus. Significant expense, constrained manufacturing, and supply-chain constraints are major barriers to widespread access to the jabs that can aid individuals in losing considerable body mass, notes the body. GLP-1 Therapy Shortage Even in the current best projected scenario, the production of GLP-1 therapies might only reach about 100 million people – under 10% of those who need them, according to the health organization. The guideline calls on countries and companies to increase access, via approaches such as voluntary licensing. A patent on semaglutide – the core component of the drug Wegovy – is scheduled to end in a number of countries in 2026. The Way Obesity Drugs Operate GLP-1 drugs mimick a biological compound to slow digestion, reduce hunger and increase feelings of fullness so individuals reduce food intake. People commonly begin shedding pounds within a few weeks of starting on the regular doses. Research suggests patients may see weight return within a year of stopping the medication, when their usual hunger come back. To be above a healthy weight increases your chance for experiencing medical conditions, like type 2 diabetes, cardiovascular issues, brain attack, and some malignancies. Obesity impacts individuals in all nations and was linked to millions of fatalities worldwide in 2024, per the WHO.